I-SPY 2 may change how clinical trials are conducted: Researchers aim to accelerate approvals of cancer drugs

Cancer

Volumn 119, Issue 11, 2013, Pages 1925-1927

  Printz, Carrie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANITUMAB; METFORMIN; NERATINIB; PACLITAXEL; PERTUZUMAB; SORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TREBANANIB; VELIPARIB;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RISK BENEFIT ANALYSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; NEOPLASMS;

EID: 84877972906     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28172     Document Type: Article

References (3)

1. President's Council of Advisors on Science and Technology. Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation. Updated September 25, 2012 whitehouse.gov/sites/default/files/ microsites/ostp/pcast-fda-final.pdf. Accessed April 17, 2013.
2. Prowell TM, Pazdur R,. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012; 366: 2438-2441.
3. DeMichele A, Berry DA, Zujewki J, et al. Developing safety criteria for introducing new agents into neoadjuvant trials [published online ahead of print on March 7, 2013]. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-2620.